Recombinant E.coli Ba71V-107 protein

The Ba71V-107 recombinant protein is derived from the Ba71V strain of African swine fever virus (ASFV), a large, double-stranded DNA virus that causes a highly contagious and often lethal disease in domestic pigs. ASFV poses significant threats to global swine industries, with no commercially available vaccine. The Ba71V strain, a cell culture-adapted and non-virulent variant of the original Ba71 isolate, has been widely used in research due to its safety profile and genetic stability. The Ba71V-107 protein is a engineered subunit antigen designed to mimic key immunogenic components of ASFV, often focusing on structural proteins like p72 (the major capsid protein) or other virulence-associated targets (e.g., CD2v or p54) involved in viral entry or host immune evasion.

Developed through recombinant DNA technology, Ba71V-107 is typically expressed in heterologous systems such as insect or mammalian cells to ensure proper post-translational modifications. It serves as a critical tool for studying ASFV antigenicity, host immune responses, and vaccine development. Researchers utilize this protein in serological assays (e.g., ELISA) to detect ASFV-specific antibodies, aiding in diagnostics and surveillance. Additionally, it has been explored as a candidate for subunit vaccines, either alone or in combination with other antigens, to induce protective immunity without risks associated with live-attenuated viruses. Recent studies highlight its potential to elicit neutralizing antibodies and T-cell responses in preclinical models, though challenges remain in achieving full protection. Its design often incorporates conserved epitopes to address ASFV’s genetic diversity, aiming for cross-protective efficacy against multiple strains. Ongoing research focuses on optimizing expression systems, adjuvant formulations, and delivery platforms to enhance its immunogenicity and practicality for field use.